1-(2,4-dihydroxy-phenyl)-ethanone-imine | 98491-68-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 1-(2,4-dihydroxy-phenyl)-ethanone-imine
• 英文别名: 1-(2,4-Dihydroxy-phenyl)-aethanon-imin；4-Ethanimidoylbenzene-1,3-diol
• CAS: 98491-68-0
• 化学式: C₈H₉NO₂
• 分子量: 151.165
• InChiKey: AMJSYDSVYHHEPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  64.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,4-dihydroxy-phenyl)-ethanone-imine 在 水 作用下， 反应 2.0h， 生成 2,4-二羟基苯乙酮
  参考文献：
  名称：

  III（III）离子与羟基酮和氮供体二级配体的发光配合物的设计，以提高发光性能和生物学作用

  摘要：

  2-基五种发光的（（III）配合物，具有2-羟基-4-乙氧基苯乙酮（主要配体）和第二个生色团，邻菲咯啉，5,6-二甲基-1,10-菲咯啉，1,10-菲咯啉和2,2-联吡啶已经通过使用经济有效的溶液沉淀法制备。采用了各种先进技术来研究结构信息。热学研究表明复合物在高达155°C的温度下具有热稳定性。分析的配合物带隙打开了这些配合物在激光系统中的应用。配合物在紫外光下的光致发光特性清楚地表明存在着显着的发射峰（5 D 0 → 7 F 2跃迁）的中心波长为611 nm，导致复合物强烈发出红色光，这突显了这些复合物在先进的光电设备中的适用性。Judd-Ofelt强度参数，内部量子效率和敏化机理证实了配合物的发光效率。该复合物显示出优异的抗微生物和抗氧化功能。

  DOI：

  10.1016/j.ica.2021.120463
• 作为产物：
  描述：

  2,4-二羟基苯乙酮 在 氨 作用下， 以 甲醇 为溶剂， 生成 1-(2,4-dihydroxy-phenyl)-ethanone-imine
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells

  摘要：

  Under hypoxia, cancer cells consume glucose and release lactate at a high rate. Lactate was recently documented to be recaptured by oxygenated cancer cells to fuel the TCA cycle and thereby to support tumor growth. Monocarboxylate transporters (MCT) are the main lactate carriers and therefore represent potential therapeutic targets to limit cancer progression. In this study, we have developed and implemented a stepwise in vitro screening procedure on human cancer cells to identify new potent MCT inhibitors. Various 7-substituted carboxycoumarins and quinolinone derivatives were synthesized and pharmacologically evaluated. Most active compounds were obtained using a palladium-catalyzed Buchwald-Hartwig type coupling reaction, which proved to be a quick and efficient method to obtain aminocarboxycoumarin derivatives. Inhibition of lactate flux revealed that the most active compound 19 (IC50 11 nM) was three log orders more active than the CHC reference compound. Comparison with warfarin, a conventional anticoagulant coumarin, further showed that compound 19 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.09.010

文献信息

• NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME
  申请人：Industry-Academic Cooperation Foundation Yonsei University

  公开号：EP3431472A2

  公开（公告）日：2019-01-23

  The present invention relates to a novel compounds for inhibiting nicotinamide phosphoribosyltransferase (NamPT), a composition comprising the same, and various uses thereof.

  本发明涉及一种用于抑制烟酰胺磷酸核糖转移酶（NamPT）的新型化合物、包含该化合物的组合物及其各种用途。
• Immobilized proteins and use thereof
  申请人：EnginZyme AB

  公开号：US10793848B2

  公开（公告）日：2020-10-06

  The invention relates to an immobilized protein material comprising a protein that is immobilized on a glass material or organic polymer through affinity tag binding. The glass material may be a porous glass material such as (hybrid) controlled porosity glass. The invention also relates to the use of an immobilized enzyme material as a heterogeneous biocatalyst in chemical synthesis. The invention further relates to a method for the immobilization of affinity tagged proteins on a glass material or organic polymer, and to a method for the purification and isolation of affinity tagged proteins by the immobilization of such proteins on a glass material or organic polymer.

  本发明涉及一种固定化蛋白质材料，包括通过亲和标签结合固定在玻璃材料或有机聚合物上的蛋白质。玻璃材料可以是多孔玻璃材料，如（混合）可控孔隙率玻璃。本发明还涉及将固定化酶材料用作化学合成中的异相生物催化剂。本发明还涉及将亲和标记蛋白质固定在玻璃材料或有机聚合物上的方法，以及通过将亲和标记蛋白质固定在玻璃材料或有机聚合物上纯化和分离亲和标记蛋白质的方法。
• Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
  申请人：CHECKMATE THERAPEUTICS INC.

  公开号：US11078195B2

  公开（公告）日：2021-08-03

  The present invention relates to a novel compounds for inhibiting nicotinamide phosphoribosyltransferase (NamPT), a composition comprising the same, and various uses thereof.

  本发明涉及一种用于抑制烟酰胺磷酸核糖转移酶（NamPT）的新型化合物、包含该化合物的组合物及其各种用途。
• Houben, Chemische Berichte, 1926, vol. 59, p. 2888
  作者：Houben

  DOI：——

  日期：——
• 5-LIPOXYGENASE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0522000A1

  公开（公告）日：1993-01-13